These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6353895)

  • 21. Health Care Financing Administration: Pharmaceutical Reimbursement Board; final maximum allowable cost determinations.
    Fed Regist; 1979 Aug; 44(169):50651-6. PubMed ID: 10297564
    [No Abstract]   [Full Text] [Related]  

  • 22. Medicaid program; prescription drugs. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Jul; 72(136):39141-245. PubMed ID: 17674494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lost in the doughnut hole. The drug benefit's woes will worsen as seniors discover shortcomings.
    Sloane T
    Mod Healthc; 2006 Jan; 36(3):24. PubMed ID: 16445210
    [No Abstract]   [Full Text] [Related]  

  • 24. States combat drug costs.
    Consum Rep; 2002 Dec; 67(12):8-9. PubMed ID: 12448442
    [No Abstract]   [Full Text] [Related]  

  • 25. Medicaid policies for HIV-related prescription drugs.
    Buchanan RJ; Smith SR
    Health Care Financ Rev; 1994; 15(3):43-61. PubMed ID: 10137797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who bears the burden of Medicaid drug copayment policies?
    Stuart B; Zacker C
    Health Aff (Millwood); 1999; 18(2):201-12. PubMed ID: 10091449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medicaid Program; Covered Outpatient Drugs. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2016 Feb; 81(20):5169-357. PubMed ID: 26859897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The state and consequences of dermatology drug prices in the United States.
    Albrecht J; Lebwohl M; Asgari MM; Bennett DD; Cook A; Evans CC; Green LJ; Hodge JA; Kourosh AS; Maloney ME; Howard LM; Olsen EA; Rosenberg SP; Rubin A; Stough DB; Taylor SC; Brod BA
    J Am Acad Dermatol; 2016 Sep; 75(3):603-605. PubMed ID: 27423978
    [No Abstract]   [Full Text] [Related]  

  • 29. MAC study confirms pharmacy losses.
    Torielli G; Gagnon JP; Lingle EW
    Am Pharm; 1982 Aug; NS22(8):31-3. PubMed ID: 6751062
    [No Abstract]   [Full Text] [Related]  

  • 30. Estimating pharmacy level prescription drug acquisition costs for third-party reimbursement.
    Kreling DH; Kirk KW
    Med Care; 1986 Jul; 24(7):590-600. PubMed ID: 3523065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Learning the list. The Preferred Drug List and how it works.
    Hinkel N
    J Ark Med Soc; 2004 Dec; 101(6):168-70. PubMed ID: 15619950
    [No Abstract]   [Full Text] [Related]  

  • 32. Medicaid: focusing on state innovation.
    Cubanski J; Kline J
    Issue Brief (Commonw Fund); 2003 Apr; (617):1-8. PubMed ID: 12693393
    [No Abstract]   [Full Text] [Related]  

  • 33. Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents.
    Ferrand Y; Kelton CM; Guo JJ; Levy MS; Yu Y
    Res Social Adm Pharm; 2011 Mar; 7(1):64-80. PubMed ID: 21397882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior-authorization programs for controlling drug spending.
    Hamel MB; Epstein AM
    N Engl J Med; 2004 Nov; 351(21):2156-8. PubMed ID: 15548775
    [No Abstract]   [Full Text] [Related]  

  • 35. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medicaid drug programs.
    McGovern J
    Nurs Homes; 1980; 29(1):30-1. PubMed ID: 10297673
    [No Abstract]   [Full Text] [Related]  

  • 37. Medicaid and indigent care issue brief: Medicaid: provider reimbursement: year end report-2003.
    Johnson P
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-25. PubMed ID: 14969256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicaid program; premiums and cost sharing. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Nov; 73(228):71827-55. PubMed ID: 19143111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceuticals & psychotropic drugs.
    Health Aff (Millwood); 2009; 28(3):723. PubMed ID: 19414880
    [No Abstract]   [Full Text] [Related]  

  • 40. The tripartite reimbursement incentive model: a new method to eliminate the discounting of the copayment charge.
    Paul SH
    Med Mark Media; 1981 Mar; 16(3):35-9. PubMed ID: 10298125
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.